Methods of treating p53 mutant cancers using OGDH inhibitors
AssigneeMemorial Sloan Kettering Cancer Center
InventorsScott Lowe, John P. Morris, IV, Scott E. Millman, Lydia Finley
Life of this patent
Estimating the term…
Abstract
The present technology relates generally to methods and compositions for treating, preventing, and/or ameliorating p53-mutant cancers in a subject in need thereof, including acute myeloid leukemia (AML), pancreatic cancer, and liver cancer, by administration of a therapeutically effective amount of a 2-oxoglutarate dehydrogenase (OGDH) inhibitor.
Claims6
A method for treating a p53 mutant cancer in a subject in need thereof comprising administering to the subject an effective amount of an OGDH inhibitor, wherein the p53 mutant cancer is acute myeloid leukemia (AML), wherein the OGDH inhibitor is an OGDH-specific inhibitory nucleic acid, succinyl phosphonate, (S)-2-[(2,6-dichlorobenzoyl) amino] succinic acid (AA6), KGD09, or KGD02, and wherein the OGDH-specific inhibitory nucleic acid is an antisense oligonucleotide, or a sgRNA.
Dependencies are inferred from the claim text.